MDLN 10-K Analysis: Why Medline's Growth Story Is a Leveraged Margin Trap

Medline Inc. grew revenue 11.5% to $28.4 billion in FY2025 — the fastest growth rate among its medical-surgical peers. But the 10-K reveals that $2.9 billion in new revenue produced just $67 million in incremental operating income. That 2.3% margin capture rate sits below the company's own 6.50% cost of debt.

The headline numbers look like a growth story. Revenue up $2,925 million. Adjusted EBITDA at $3,467 million. The largest US IPO of 2025, priced at $29, trading near $42 within weeks. Medline is the largest private-label medical-surgical manufacturer and distributor in the United States, operating 30 manufacturing facilities, 69 distribution centers, and a 2,000-truck fleet to serve 1,600+ health system relationships. By every top-line measure, the IPO narrative was working.

But the 10-K documents a company running harder and harder to stand still inside a capital structure that demands more than operations can deliver. ROIC of 5.96% sits 54 basis points below the 6.50% cost of debt — making Medline the only company among its med-surg peers actively destroying value on every debt-funded dollar. A Q4 gross margin cliff to 24.6% (down 270 basis points from Q4 2024) signals accelerating deterioration, not stabilization. And a potential $11 billion Tax Receivable Agreement owed to PE sponsors means public shareholders capture only 10 cents on every dollar of tax benefits the IPO reorganization generates. The filing reveals why this growth trap is structural — Medline has the strongest customer lock-in in med-surg distribution, but the same customer structure that guarantees volume also caps pricing power.

The Growth Trap: When 11.5% Revenue Growth Produces 2.3% Incremental Margin

The bull case for Medline starts and ends with the top line. Revenue grew $2,925 million to $28,432 million in FY2025, a rate that outpaced BDX (+6.2%) and MMM (+1.1%) by a wide margin. For a company fresh off the largest US IPO of the year, the growth narrative appeared to be intact.

The 10-K dismantles that narrative with a single calculation. Operating income grew approximately $67 million on $2,925 million of incremental revenue — an incremental operating margin of just 2.3%. For every new dollar of revenue Medline generated, the company captured barely two cents of operating profit. At that rate, revenue would need to grow roughly 3× faster just to cover the 6.50% cost of debt.

The filing confirms why margin capture was so poor. Management acknowledged that growth was entirely volume-driven with no pricing contribution:

"Organic net sales growth was substantially all related to increased volumes with pricing having an immaterial impact."

This zero pricing power is not a temporary condition — it is structural to how Medline sells. Three Group Purchasing Organizations negotiate pricing on behalf of the majority of Medline's hospital customers. When tariffs raised input costs by 115 basis points of gross margin (approximately $327 million on $28.4 billion in revenue), those costs could not be passed through. The tariff drag hit hardest in Q4, when gross margin fell to 24.6% — a 270 basis point collapse from Q4 2024 and a sharp cliff from the 27.2% average across Q1-Q3 2025. Q4 cost of goods sold grew 19.1% while revenue grew 14.8%, a 430 basis point spread between cost escalation and revenue capture.

Meanwhile, working capital consumed $783 million in cash — driven by a $355 million increase in accounts receivable, $264 million in tariff-driven inventory pre-buying, and a $166 million litigation accrual payment. Operating cash flow actually declined $25 million to $1,744 million despite the $2.9 billion revenue increase. Revenue growth translated to zero incremental cash flow. Medline Inc. grew revenue $2.9 billion in FY2025 but captured only $67 million in incremental operating income — a 2.3% margin capture rate that is less than half the company's own 6.50% cost of debt.

Whether Q4's 24.6% gross margin represents a temporary tariff-driven trough or a new baseline is the single most important near-term data point. If Q1 2026 gross margin recovers above 26.0%, the growth trap thesis weakens. If it stays below 25.5%, margin compression is structural and the capital structure math becomes significantly harder.

The LBO Return Deficit: A Capital Structure That Earns Less Than It Costs

The 2021 leveraged buyout that took Medline private at a $34 billion valuation left behind a capital structure that, four years later, still earns less than it costs. Medline's return on invested capital of 5.96% falls 54 basis points below its weighted average cost of debt of 6.50%. Every dollar of debt-funded investment destroys value rather than creates it.

This is not a generic "highly leveraged" observation — it is a structural deficit with five identifiable components. We decompose the ROIC gap into a framework we call the LBO Return Deficit Decomposition, which quantifies what must change for Medline to cross from value destruction to value creation.

Four of the five components are structural — embedded in the capital structure by the LBO and impossible to manage away through operations. The $704 million in annual intangible amortization from acquired customer relationships, developed technology, and trade names will persist for 14+ years (total remaining amortization: $10,063 million). This amortization represents 70% of Medline's $1,011 million D&A expense and permanently inflates the invested capital denominator used to calculate ROIC. While Adjusted EBITDA adds it back, ROIC cannot.

The IPO itself was structured primarily as debt repayment, not growth capital. Of $5,078 million in net IPO proceeds, $4,023 million (79.2%) went directly to repaying LBO-era term loans:

"used the proceeds (net of underwriting discounts and commissions) from the issuance of 179,000,000 shares ($5,078 million) in the IPO to purchase an equivalent number of newly issued Common Units from Medline Holdings, which Medline Holdings has in turn used $731 million...to repay in full all outstanding Euro Term Loans and $3,292 million...to repay a portion of the outstanding Dollar Term Loans."

Even after deleveraging with IPO proceeds, $12,561 million in debt remains. The weighted average cost of 6.50% reflects a mix of $4,255 million in variable-rate loans at approximately 7.10%, $6,000 million in fixed-rate secured loans at 4.79%, and $2,500 million in unsecured notes at 5.61%. Approximately $8.5 billion matures in 2029 — a refinancing wall just four years post-IPO. If rates remain elevated, refinancing at similar or higher terms would perpetuate the return deficit for another cycle.

Among med-surg peers, Medline is the outlier. BDX earns a +2.20 percentage point positive spread — it creates value on its debt. MMM earns +12.1 percentage points. Medline is the only company in the comparison with a negative spread. The breakeven math is straightforward: to achieve ROIC equal to the cost of debt, NOPAT must grow approximately $186 million (roughly 9%). That requires either $2.6 billion in incremental revenue at current margins, 90 basis points of NOPAT margin expansion, or $2.9 billion in debt paydown — approximately two years of free cash flow allocated entirely to deleveraging.

Medline's return on invested capital of 5.96% falls 54 basis points below its 6.50% cost of debt, making it the only company among its med-surg peers actively destroying value on every debt-funded dollar of investment. The covenant EBITDA used for debt compliance includes an additional $230 million in add-backs beyond Adjusted EBITDA — including run-rate contributions from signed contracts and cost savings — inflating the leverage metric lenders see. The gap between economic reality and covenant compliance is growing.

The Triple Tax Squeeze: From 7.3% ETR to Reality

Medline's 7.3% effective tax rate in FY2025 flatters net income by $159 million to $275 million annually relative to normalized rates. Three converging forces will push that rate toward 15-20%+, and the Tax Receivable Agreement ensures that 90% of any remaining tax benefits flow to PE sponsors rather than public shareholders.

The mechanism sustaining the low ETR is transparent in the filing. International operations generated 25.6% of pretax income ($319 million) on just 6.9% of revenue ($1,953 million) — an implied international pretax margin of 16.3% versus 3.5% for US operations. That 4.7× margin differential, combined with confirmed tax holidays in the UAE, Panama, and Dominican Republic, signals transfer pricing arrangements routing profits through low-tax jurisdictions.

The first force is Pillar Two — the OECD's global minimum tax designed to impose a 15% floor on large multinationals' foreign earnings. The FY2025 tax provision nearly doubled from $46 million to $91 million, partly from early Pillar Two effects. Medline's 7.3% effective tax rate is sustained by routing 25.6% of pretax income through international tax holiday jurisdictions on just 6.9% of revenue — a 4.7× margin differential that Pillar Two global minimum tax is designed to eliminate.

The second force is Section 163(j). The filing discloses a $142 million interest expense carryforward — up from zero in the prior year — meaning Medline could not fully deduct its $812 million net interest expense under the 30%-of-adjusted-taxable-income limitation. As the company completes its transition from pass-through partnership taxation to corporate entity taxation, the 163(j) constraint will tighten, reducing the tax shield value of $12.6 billion in debt.

The third force is the TRA itself. The Tax Receivable Agreement obliges Medline to pay pre-IPO PE owners 90% of certain tax benefits realized from the IPO reorganization — a higher rate than the 85% figure widely cited in coverage:

"if the Unitholders had exchanged all of the Common Units that they held on December 31, 2025, and assuming all Incentive Units had been converted to Common Units and subsequently exchanged for shares of Class A common stock at a price of $42.00 per share of Class A common stock as of such date, we would, as a result of such hypothetical exchange, have recorded an additional tax receivable agreement liability of approximately $7,458 million, generally payable over a 15-year period."

The current TRA liability stands at $3,542 million — 33% of total equity. If all Common Units were exchanged, the total potential obligation reaches $11,000 million, or 102% of equity and 32.3% of market cap. The $256 million in NOL carryforward deferred tax assets created by the IPO reorganization will shield some future income from tax, but 90% of that benefit flows to pre-IPO owners under the TRA. Public shareholders capture approximately 10 cents on every dollar of tax savings.

Every earnings model for Medline must answer a single question before assigning a multiple: what is the sustainable ETR? If the answer is 15%, net income drops $96 million (-8.3%). If 20%, the decline is $159 million (-13.7%). If 25%, it is $221 million (-19.1%). The market price implies the current 7.3% rate persists — the filing strongly suggests it will not.

The Moat Paradox: Volume Lock-In Without Pricing Power

Medline's competitive position presents a genuine paradox. The Prime Vendor model — multi-year exclusive distribution contracts with health systems — is the strongest quantifiable customer lock-in in med-surg distribution. The filing confirms that Prime Vendor relationships generated $18,033 million in revenue (63.4% of total), grew $2,000 million in FY2025 (+12.5%), and achieved a 5.4× win-to-loss ratio: $1,229 million in new customer wins versus $227 million in losses.

This is a real moat. The switching costs for a hospital moving its entire supply chain from one Prime Vendor to another are measured in years and millions of dollars of implementation expense. Medline's net customer additions of roughly $1 billion annually confirm that the lock-in is not just defensive — it actively captures market share.

But the same filing reveals why this moat cannot protect margins:

"approximately $19.7 billion (or 69% of consolidated net sales and 74% of U.S. net sales) was from sales to member hospitals under contract with our largest GPOs: Vizient Supply, LLC, HealthTrust Purchasing Group, L.P., and Premier Healthcare Alliance, L.P."

Three Group Purchasing Organizations channel $19.7 billion — 69% of Medline's consolidated sales and 74% of US sales. The GPOs negotiate pricing on behalf of thousands of individual hospitals, creating an asymmetry: Medline has switching power over individual hospitals (fragmented, high switching costs), while GPOs have pricing power over Medline (concentrated, competitive bidding). The moat locks in volume but structurally prevents the pricing actions needed to pass through tariff costs.

The tariff impact illustrates the paradox precisely. The Medline Brand segment — where vertical integration creates the highest margins — absorbed 235 basis points of tariff drag on its EBITDA margin, partially offset by 47 basis points of freight savings:

"Medline Brand Segment Adjusted EBITDA margin decreased to 24.3% from 26.1%, primarily driven by 235 basis points from higher import costs due to tariffs, partially offset by 47 basis points from lower freight costs."

Meanwhile, the Supply Chain Solutions segment — where Medline merely distributes third-party national brands — gained 50 basis points of margin. The manufacturing that creates the moat is also the vector that concentrates tariff exposure. And a 41% increase in the credit loss allowance ($108 million to $152 million) growing 3.6× faster than accounts receivable suggests that customer credit quality is deteriorating alongside margin compression.

The verdict on the moat paradox is clear: the Prime Vendor moat protects volume but cannot protect margins. Medline's Prime Vendor model generates $18 billion in annual revenue through 1,600+ exclusive relationships with a 5.4× win-to-loss ratio, but 69% of the company's sales flow through just three group purchasing organizations that structurally cap pricing power. The moat guarantees that Medline will not lose customers, but it equally guarantees that Medline cannot raise prices fast enough to offset tariff headwinds — leaving the growth trap from Section 1 as a permanent feature of the business model, not a temporary condition. The company is investing $500 million in FY2026 capital expenditures (up from $447 million) to build manufacturing capacity in Mexico, signaling a multi-year effort to shift production away from tariff-exposed geographies. But even if Mexico manufacturing reduces future tariff drag, the GPO pricing ceiling remains.

What to Watch: Tracking the Thesis

Three data points will determine whether Medline's leveraged margin trap is permanent or transitory.

1. Q1 2026 Gross Margin (the most important single data point)

Q4's 24.6% gross margin was the worst quarter since the IPO. If Q1 2026 recovers above 26.0%, the compression was cyclical — driven by tariff pre-buying and one-time inventory dynamics. If it remains below 25.5%, the margin cliff is structural and the ROIC deficit math becomes significantly more challenging. This single metric resolves the "trough vs trend" question that underpins the entire thesis.

2. Effective Tax Rate Trajectory

The FY2025 ETR nearly doubled from 3.7% to 7.3%. Watch whether Q1 2026 shows further step-up toward 10-12% as Pillar Two effects annualize and corporatization continues. An ETR above 15% in any quarter would confirm the tax normalization thesis is accelerating faster than the market expects.

3. Pricing Power Emergence

Any quarter where management acknowledges a measurable pricing contribution — even 50 basis points — would break the "zero pricing power" finding. This is the hardest metric to move because GPO contracts structurally resist price increases, but it is the only operational lever that could close both the margin gap and the ROIC deficit simultaneously.

4. Debt Paydown Pace

After repaying $4.0 billion with IPO proceeds, Medline still carries $12.6 billion in debt. Any accelerated paydown — from asset sales, additional equity raises, or above-trend free cash flow — directly narrows the ROIC deficit. The $8.5 billion 2029 maturity wall is the deadline by which meaningful progress must be visible.

5. Incremental Operating Margin

The 2.3% capture rate in FY2025 is the metric that summarizes everything. A sustained improvement to 8%+ would demonstrate that the business can convert growth into value. Below 5%, the growth trap is confirmed regardless of what happens to tariffs or taxes.

At $42 per share, Medline trades at 13.7× filing Adjusted EBITDA, implying 13-17% annual EBITDA growth for five years to reach terminal value at 10-12× multiples. The filing shows actual Adjusted EBITDA growth of 3.2%. The bull case requires tariff reversal, pricing power emergence, and EBITDA margin expansion from 12.2% toward 15%+ — none of which the filing supports, and all of which the filing actively contradicts with specific, quantified evidence. At $42, the market is pricing a growth-and-margin story. The 10-K documents a leveraged margin trap.

Frequently Asked Questions

What is Medline's incremental operating margin, and why does it matter?

Medline's incremental operating margin in FY2025 was 2.3% — meaning the company captured just $0.023 of operating profit per incremental revenue dollar from its $2.9 billion in new sales. This matters because at 2.3%, even double-digit top-line growth barely moves profitability. Medline's cost of debt is 6.50%, meaning the company needs incremental margins roughly 3× higher just to cover the cost of its LBO-era debt. The primary drags were tariff costs (115bps of gross margin) and the absence of pricing power.

How does Medline's ROIC compare to its cost of debt?

Medline's ROIC of 5.96% sits 54 basis points below its 6.50% cost of debt. This means every dollar of debt-funded investment earns less than it costs — a negative value spread. Among med-surg peers, BDX earns a +2.2pp positive spread and MMM earns +12.1pp. Medline is the only company in the comparison actively destroying value on its debt, a structural consequence of the 2021 $34B LBO that left $12.6B in debt at high rates.

What is the Tax Receivable Agreement (TRA), and how large is it?

The TRA obliges Medline to pay pre-IPO PE owners (Blackstone, Carlyle, Hellman & Friedman) and the Mills family 90% of certain tax benefits realized from the IPO reorganization. The current TRA liability is $3,542M (33% of total equity). If all Common Units were exchanged, the total potential obligation reaches approximately $11,000M — 32.3% of market cap. Public shareholders bear full business risk but receive only ~10% of tax benefits.

Why did Medline's Q4 2025 gross margin collapse?

Q4 2025 gross margin fell to 24.6%, down 270 basis points from Q4 2024's 27.3%. This was significantly worse than the Q1-Q3 2025 implied average of 27.2%, representing a sharp cliff. The primary driver was tariff escalation: Q4 COGS grew 19.1% versus revenue growth of 14.8% — a 430bps spread. Whether Q1 2026 gross margin recovers above 26.0% is the key near-term test of whether this compression is structural or cyclical.

How does vertical integration help and hurt Medline simultaneously?

Medline manufactures roughly one-third of its products in 30 owned facilities, creating a margin advantage: Medline Brand earns 24.3% EBITDA margin versus 5.5% for Supply Chain Solutions. However, this same manufacturing ownership concentrates tariff exposure. Medline Brand absorbed 235bps of tariff drag while SCS gained 50bps from operating leverage — the high-margin segment bore the tariff hit while the low-margin segment benefited.

What is the Section 163(j) issue and why does it matter?

Section 163(j) limits business interest deductions to 30% of adjusted taxable income. Medline's filing reveals a $142M interest expense carryforward — up from $0 in the prior year — meaning the company could not fully deduct its $812M net interest expense in FY2025. As the company corporatizes, the 163(j) cap is expected to tighten, eroding the tax shield value of $12.6B in leverage.

How concentrated is Medline's customer base?

Medline has two layers of concentration. The top 5 US customers represent $3.2B (11.3% of sales) — seemingly diversified. But three Group Purchasing Organizations — Vizient, HealthTrust, and Premier — account for $19.7B or 69% of consolidated net sales. GPOs negotiate pricing on behalf of thousands of hospitals. A single GPO contract renegotiation could affect billions in revenue.

What does the debt maturity schedule look like?

Medline carries $12.6B in total debt: $4,255M variable-rate at SOFR + 1.75% (~7.10%), $6,000M fixed-rate at 4.79%, and $2,500M unsecured notes at 5.61%. The weighted average cost of debt is 6.50%. Approximately $8.5B matures in 2029 — just 4 years post-IPO — creating a refinancing wall that could perpetuate the ROIC deficit if rates remain elevated.

How does Medline's valuation compare to implied growth requirements?

At $42/share, Medline trades at 13.7× filing Adjusted EBITDA ($3,467M), implying 13-17% annual EBITDA growth for 5 years. In FY2025, Adjusted EBITDA grew just 3.2%. The valuation assumes margin expansion and sustained double-digit revenue growth — neither of which the filing supports. The price assumes tariff reversal, pricing power emergence, and ETR stability, all contradicted by filing evidence.

What would change the thesis?

Three data points would falsify the thesis: (1) Q1 2026 gross margin above 26.0%, proving Q4's 24.6% was a trough. (2) Management announcing pricing actions with measurable pass-through — any quarter showing pricing contribution above zero. (3) Incremental operating margin above 8% in any quarter, demonstrating margin capture without tariff relief. Additionally, accelerated debt paydown would directly improve the ROIC vs cost of debt spread.

How much does Pillar Two affect Medline's tax rate?

The FY2025 tax provision nearly doubled ($46M to $91M, +97.8%) partly due to Pillar Two global minimum tax. International operations generated a 16.3% pretax margin versus 3.5% for US operations — a 4.7× differential suggesting transfer pricing through tax holiday jurisdictions (UAE, Panama, Dominican Republic). Pillar Two's 15% minimum rate will erode this optimization, pushing consolidated ETR from 7.3% toward 15-20%.

What is the LBO Return Deficit Decomposition?

A 5-component framework breaking down why Medline's ROIC (5.96%) falls below its cost of debt (6.50%). The five components are: (1) $704M/yr intangible amortization inflating the invested capital base, (2) TRA cash leakage at 90% of tax benefits, (3) tax normalization from 7.3% toward 15-20%+ ETR, (4) 163(j) interest deductibility cap with $142M growing carryforward, and (5) 2.3% incremental operating margin — the only component management can control.

Methodology

Data Sources

This analysis uses data from Medline Inc.'s FY2025 10-K filing (filed February 25, 2026) and the Q4 2025 8-K earnings release (filed February 25, 2026). Financial metrics are computed by MetricDuck's automated pipeline covering 5,000+ US public companies. Peer data for BDX and MMM sourced from their most recent public filings via MetricDuck. Enterprise value calculated as: $34,020M market cap + $12,561M total debt + $2,813M noncontrolling interest − $1,942M cash = $47,452M.

Limitations

• First-year public company. MDLN has no prior public filing history. All trend analysis is limited to single-year comparisons (FY2024 vs FY2025). Multi-year CAGRs, historical margin trends, and management guidance track records are unavailable.
• FY2026 guidance not captured. The 8-K mentions "full year 2026 guidance" but specific revenue/EBITDA targets were not available in extracted sections. Only CapEx guidance ($500M) is confirmed. The valuation analysis is backward-looking against FY2025 actuals.
• Peer set limitation. Direct med-surg distribution peers (Cardinal Health/CAH, McKesson/MCK) would provide more informative benchmarking but were not in the assigned peer set. BDX and MMM are the closest available comparisons.
• Pipeline vs filing EBITDA discrepancy. MetricDuck's automated pipeline reports Adjusted EBITDA of $3,299M; the filing states $3,467M — a $168M (5.1%) gap due to incomplete add-backs. All article EBITDA references use the filing figure ($3,467M).
• TRA payment timing uncertainty. The TRA obligation has no disclosed payment schedule — payments are contingent on realizing tax benefits. The analysis uses magnitude-based framing rather than present value calculations.
• Quarterly breakdown limited to Q4. The Q4 gross margin of 24.6% is derived from the 8-K. Q1-Q3 individual quarter breakdowns are not available; the 27.2% Q1-Q3 average may mask intra-year variation.

Disclaimer:

This analysis is for informational purposes only and does not constitute investment advice. The author does not hold positions in MDLN, BDX, or MMM. Past performance and current metrics do not guarantee future results. All data is derived from public SEC filings and may contain errors or omissions from the automated extraction process.